Cardiff Oncology, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 |
| Operating income | -$49.0M | -$48.7M | -$45.4M | -$39.9M | -$28.9M |
| Operating expenses | $49.6M | $49.3M | $45.9M | $40.3M | $29.2M |
| Cash from operations | -$37.9M | -$37.7M | -$30.9M | -$33.8M | -$23.0M |
| Capital expenditure | $44,000 | $80,000 | $582,000 | $1.0M | $205,000 |
| Free cash flow | -$38.0M | -$37.8M | -$31.5M | -$34.8M | -$23.2M |
| Total assets | $61.9M | $97.2M | $81.6M | $116.2M | $149.5M |
| Total liabilities | $16.5M | $14.2M | $11.9M | $9.8M | $9.1M |
Shares outstanding 68.4M · Free float 89.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.